Profile
Keith S.
Ehrlich worked as an Auditor at Coopers & Lybrand LLP from 1980 to 1991.
He then worked as Treasurer & Finance Director at Vertex Pharmaceuticals, Inc. from 1991 to 1993, followed by CFO, Treasurer, VP-Finance & Administration at OraVax, Inc. from 1993 to 1998.
He then worked as CFO, Treasurer, SVP-Finance & Administration at Dyax Corp.
in 1998 and CFO, Vice President-Finance & Administration at Argentys Corp.
from 1999 to 2003.
He joined Synta Pharmaceuticals Corp.
in 2004 and worked as CFO, Vice President-Finance & Administration until 2014.
From 2015 to 2017, he worked as CFO & Principal Accounting Officer at AVEO Pharmaceuticals, Inc. Mr. Ehrlich received his undergraduate degree from Drew University and his MBA from Rutgers State University of New Jersey.
Former positions of Keith S. Ehrlich
| Companies | Position | End |
|---|---|---|
| AVEO PHARMACEUTICALS, INC. | Director of Finance/CFO | 2017-05-31 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Director of Finance/CFO | 2014-12-07 |
| DYAX CORP. | Director of Finance/CFO | 1999-06-30 |
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a private company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Director of Finance/CFO | 1997-12-31 |
Training of Keith S. Ehrlich
| Drew University | Undergraduate Degree |
| Rutgers State University of New Jersey | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Private companies | 6 |
|---|---|
OraVax, Inc.
OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a private company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Health Technology |
Dyax Corp.
 Dyax Corp. Pharmaceuticals: MajorHealth Technology Dyax Corp. engages in discovery, development and commercialization of novel biotherapeutics. The company was founded by Henry E. Blair in 1989 and is headquartered in Burlington, MA. | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
| Coopers & Lybrand LLP | Commercial Services |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Keith S. Ehrlich
